Pappas-founded Afferent Pharmaceuticals acquired by Merck for $500 million, plus up to $750 million in milestone payments.
learn more »
cultivating innovation, and
advancing patient care.
knowledge and a history of
success in life sciences.
guiding innovative life
science companies along
the path to success.
centers and tapping into
Pappas Ventures is focused exclusively on investing in the life sciences sector across North America. Our entire team works closely with our portfolio companies and investors to deliver superior results for everyone involved.
see why our singular focus is our strength »
An expert team dedicated to success.
click here »
A portfolio of innovative companies.